LMR Partners’s Actinium Pharmaceuticals ATNM Stock Holding History

LMR Partners’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16,943	Closed	-$160K	–	904
2023 Q1	$160K	Buy	+16,943	New	+$179K	﹤0.01%	881

Other funds holding ATNM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

LMR Partners's ATNM Position: Q2 2023 in Review

LMR Partners sold out of Actinium Pharmaceuticals (ATNM) in Q2 2023, closing a stake of 16,943 shares — an estimated $160K sold.

LMR Partners first reported a position in ATNM in Q1 2023 and held it in 1 quarter. The position peaked at $160K in Q1 2023. 71 funds tracked by Wall St. Rank hold ATNM as of Q2 2023.

LMR Partners reported no remaining Actinium Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
LMR Partners sold 16,943 Actinium Pharmaceuticals shares in Q2 2023, an estimated $160K.
LMR Partners first reported a position in Actinium Pharmaceuticals in Q1 2023 and held it in 1 quarter.
LMR Partners's Actinium Pharmaceuticals position peaked at $160K in Q1 2023.
71 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2023.

Based on LMR Partners's 13F filing for Q2 2023, filed 14 Aug 2023.